These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 6409375)

  • 41. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease.
    Golbe LI; Lieberman AN; Muenter MD; Ahlskog JE; Gopinathan G; Neophytides AN; Foo SH; Duvoisin RC
    Clin Neuropharmacol; 1988 Feb; 11(1):45-55. PubMed ID: 3127050
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Selegiline, fluoxetine, and depression in Parkinson's disease.
    Garcia-Monco JC; Padierna A; Gomez Beldarrain M
    Mov Disord; 1995 May; 10(3):352. PubMed ID: 7651457
    [No Abstract]   [Full Text] [Related]  

  • 43. Selegiline and Parkinson's disease. Protective and symptomatic considerations.
    Golbe LI; Langston JW; Shoulson I
    Drugs; 1990 May; 39(5):646-51. PubMed ID: 2112994
    [No Abstract]   [Full Text] [Related]  

  • 44. [Do monoamine oxidase B inhibitors represent hope for Parkinson's disease patients?].
    Delwaide PJ
    Rev Med Liege; 1987 Jul 1-15; 42(13-14):639-43. PubMed ID: 3112896
    [No Abstract]   [Full Text] [Related]  

  • 45. Why another anti-Parkinson drug?
    Shreeve C
    Nurs Mirror; 1984 Feb; 158(9):38-40. PubMed ID: 6422448
    [No Abstract]   [Full Text] [Related]  

  • 46. A double-blind, controlled study of high-dose L-deprenyl in the treatment of Parkinson's disease.
    Frankel JP; Kempster PA; Stibe CM; Eatough VM; Nathanson M; Lees AJ; Stern GM
    Clin Neuropharmacol; 1989 Oct; 12(5):448-51. PubMed ID: 2514981
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A new approach to the treatment of Parkinson's disease. Symposium, Turku, Finland, May 27, 1983.
    Acta Neurol Scand Suppl; 1983; 95():1-144. PubMed ID: 6428139
    [No Abstract]   [Full Text] [Related]  

  • 48. Deprenyl in Parkinson disease.
    Longstreth WT
    Neurology; 1981 Dec; 31(12):1578. PubMed ID: 6796906
    [No Abstract]   [Full Text] [Related]  

  • 49. [A long-term clinical effect of selegiline hydrochloride on Parkinson's disease].
    Mizuno Y; Kondo T; Takubo H; Yokochi F
    No To Shinkei; 1994 May; 46(5):465-71. PubMed ID: 8060685
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease.
    Brannan T; Yahr MD
    Ann Neurol; 1995 Jan; 37(1):95-8. PubMed ID: 7818264
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (-)deprenyl administration.
    Reynolds GP; Riederer P; Sandler M; Jellinger K; Seemann D
    J Neural Transm; 1978; 43(3-4):271-7. PubMed ID: 745019
    [TBL] [Abstract][Full Text] [Related]  

  • 52. New strategies in the treatment of Parkinson's disease. Symposium. Copenhagen, Denmark, January 26-27, 1989. Proceedings.
    Acta Neurol Scand Suppl; 1989; 126():1-219. PubMed ID: 2515714
    [No Abstract]   [Full Text] [Related]  

  • 53. Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study.
    Ben-Shlomo Y; Lees A;
    Neurology; 2001 Jul; 57(2):369; author reply 369-70. PubMed ID: 11480425
    [No Abstract]   [Full Text] [Related]  

  • 54. Role of selegiline as initial monotherapy in early Parkinson's disease.
    Bhatia M; Jain S; Maheshwari MC
    J Assoc Physicians India; 1994 Jan; 42(1):30-2. PubMed ID: 7836244
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long term treatment with L-deprenyl.
    Birkmayer W
    J Neural Transm; 1978; 43(3-4):239-44. PubMed ID: 745016
    [No Abstract]   [Full Text] [Related]  

  • 56. The contribution of amphetamine metabolites of (-)-deprenyl to its antiparkinsonian properties.
    Elsworth JD; Sandler M; Lees AJ; Ward C; Stern GM
    J Neural Transm; 1982; 54(1-2):105-10. PubMed ID: 6809891
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of Parkinson's disease.
    Lieberman A
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):339-43. PubMed ID: 8507903
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
    Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Current status of selegiline as a neuroprotective agent in Parkinson's disease.
    Olanow CW; Mytilineou C; Tatton W
    Mov Disord; 1998; 13 Suppl 1():55-8. PubMed ID: 9613720
    [No Abstract]   [Full Text] [Related]  

  • 60. Drug trial for Parkinson's.
    Lewin R
    Science; 1987 Jun; 236(4807):1420. PubMed ID: 3109033
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.